FDA removes hold on Vion's late-stage cancer trial

Vion Pharmaceuticals has received a green light from the FDA to resume studying the cancer drug Cloretazine as regulators removed a clinical hold on a Phase III trial of the therapy. The late stage study of Cloretazine in combination with cytarabine for acute relapsed myeloid leukemia was put on hold after researchers raised concerns over an increase of death relative to the control arm of the trial matching cytarabine and a placebo. But a review found no reason to believe there was any unexpected toxicity playing a role in the deaths.

- read this release for more
- here's the report from Thomson Financial

Suggested Articles

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.

ADC Therapeutics nearly went through the entire alphabet before trying, twice, to get off an IPO. Now, it’s looking to become a commercial biotech.

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.